Kadans Science Partner will add Windrush Innovation Centre in Oxford, UK to its Pan-European portfolio. The asset will be freehold acquired from Tozi Limited. Kadans intends to demolish the existing building and create over 60,000 sq ft of new high specification laboratory and office space in partnership with the tenant, Oxford Biomedica.
Oxford is a global centre of excellence in life science innovation. The cluster is anchored by the University of Oxford which was recently named the number 1 university in the world (Times World University Ranking 2022). The Oxford cluster spans a whole…
PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases
$7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group. Existing investors Cambridge Enterprise, University of Cambridge Enterprise Fund VIII, managed by Parkwalk Advisors Heyford Trust, o2h Ventures, Martlet Capital, Arrowfield Capital, Wren Capital and experienced life sciences angel investors including Jonathan Milner also participated
PharmEnable has developed a proprietary drug…
YouGov, on behalf of Bidwells, are carrying out a survey of the Tech sector.
The purpose of the study is to help the real estate sector and policy makers understand the requirements and preferences of organisations so they might better provide property and infrastructure for your industry in the future.
The survey looks at the location and property requirements of the tech sector overall. There are also some additional questions for companies, currently or potentially, working in the areas of health and life sciences.
The results of the survey will be published in July and will be made…
Click here to view the May 2023 edition of The Meeting Place.
The University of Birmingham’s Clinical Immunology Service (CIS) is soon to become the anchor tenant at the forthcoming Precision Health Technology Accelerator (PHTA), after signing up to occupy ~10,000 sq ft of the custom-built flagship research facility.
Providing a comprehensive range of accredited lab services to facilitate the diagnosis of autoimmune and neuroimmunological disease, blood cancers, primary and secondary immunodeficiency, infections and allergy, the CIS receives more than 100,000 blood, marrow, urine and other samples per year.
The CIS team offers the only service of its…
Early-stage life sciences enterprises are set to benefit from a unique new collaboration between Birmingham’s Precision Health Technologies Accelerator (PHTA) and Oxford Science Enterprises (OSE).
The partnership will focus on helping high-growth health technology and life sciences companies to scale, primarily through access to high-quality lab and innovation space, while also catalysing cross-regional collaboration between academics and enterprises.
PHTA is the University of Birmingham (UoB)’s flagship life sciences research accelerator, where entrepreneurs, start-ups and scale-ups…
Stevenage, 18th May, 2023 – Kadans Science Partner (Kadans), the European leader in developing science and technology real estate, today announces the launch of Sycamore House, a new laboratory and office facility for innovative, high-growth life science companies and Kadans’ first completed development in the UK. By adding Sycamore House to the portfolio, Kadans is furthering its goal to create one strong knowledge-sharing ecosystem of science parks across Europe. Their portfolio now comprises over 45 buildings and numerous projects under development in the Netherlands, the United Kingdom,…
Pharmanovia’s leading medicine brands to be combined with Closed Loop Medicine’s technology to provide dose optimized personalized therapies
Global (ex-US) co-development and commercialization partnership to initially focus on next-generation drug + software product solutions for the treatment of hypertension
London and Basildon, UK, 17 May 2023: Closed Loop Medicine Ltd, a leading TechBio company, developing combination prescription drug plus software therapy products that enable personalized dose optimization, and Pharmanovia, a global pharmaceutical company that…
AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.
Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cells for treatment of leukemia and lymphoma. Consequently, there is now rapid growth in research on the therapeutic uses of CAR-T cells.
Increasingly CAR-T cell therapies are being employed as a strategy to redirect a patient’s T-cells to target and destroy specific tumor cells. Researchers have…
Accelerate@Babraham, the Babraham Research Campus’ programme supporting early-stage life science ventures, announces new cohort
Cambridge, UK, 16th May 2023: Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to officially welcome six new ventures to Accelerate@Babraham 2023.
Chosen via a rigorous selection process which culminated in short-listed companies being interviewed by representatives of the Babraham Research Campus executive team and all the programme’s strategic partners,…